Improvement in precision of counting actinic keratoses

Actinic keratoses (AKs) often serve as a primary endpoint for clinical studies. However, reliability of counting these lesions is poor, even among expert dermatologists.

[1]  J Kalivas,et al.  Reliability of counting actinic keratoses before and after brief consensus discussion: the VA topical tretinoin chemoprevention (VATTC) trial. , 2001, Archives of dermatology.

[2]  Neil Swanson,et al.  Ingenol mebutate gel for actinic keratosis. , 2012, The New England journal of medicine.

[3]  P. V. Van Ness,et al.  Testing Measurement Reliability in Older Populations , 2008, Journal of aging and health.

[4]  A. Marghoob,et al.  Agreement on the Clinical Diagnosis and Management of Cutaneous Squamous Neoplasms , 2010, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[5]  N. Fenske,et al.  Actinic keratoses: past, present and future. , 2010, Journal of drugs in dermatology : JDD.

[6]  R. Marks,et al.  Spontaneous remission of solar keratoses: the case for conservative management , 1986, The British journal of dermatology.

[7]  A. Green,et al.  High incidence and regression rates of solar keratoses in a queensland community. , 2000, The Journal of investigative dermatology.

[8]  S. Feldman,et al.  Pharmacoeconomic Considerations in Treating Actinic Keratosis , 2012, PharmacoEconomics.

[9]  M. Stadecker,et al.  Clinical recognition of actinic keratoses in a high-risk population: how good are we? , 2005, Archives of dermatology.

[10]  Suephy C. Chen,et al.  Reliable methods to evaluate the burden of actinic keratoses. , 2006, The Journal of investigative dermatology.

[11]  E. Veledar,et al.  Reliability of quantification measures of actinic keratosis , 2013, The British journal of dermatology.